In a significant move, the Department of Justice (DOJ) has settled criminal antitrust charges with Teva Pharmaceuticals and Glenmark Pharmaceuticals that amount to a hefty $305 million. This case presented by the Antitrust Division of the DOJ indicates a continued trend of aggressive prosecution.
However, the Antitrust Division’s record in criminal cases has received critical attention due to a striking series of setbacks. This includes contentious losses in chicken price-fixing instances and defeats in criminal labor market cases, indicating a potential need for a strategic shift in their approach. The case against Teva and Glenmark, thus, represents a much-needed win for the Division amidst this backdrop.Read More
The legal implications of the settlement pose considerable interest for the legal community, particularly for those in corporate law and antitrust law. This case will undoubtedly guide legal strategy for similar future cases, further shaping the landscape of criminal antitrust litigation.